Ipsen to acquire Clementia Pharmaceuticals  

A shared and strengthened commitment to patients with rare diseases

Discover Transaction Infographics

Ipsen and Clementia Pharmaceuticals announced that they have entered into a definitive agreement for Ipsen to acquire Clementia Pharmaceuticals, including its key late-stage clinical asset palovarotene, an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas (MO) and other diseases.  

Continuing the transformation of Ipsen: • Accelerating a global Rare Disease organization with the mission to bring treatment options for ultra-orphan diseases to patients worldwide • Executing on key strategic objective to increase the value of the pipeline with innovative first-in-class or best-in-class assets • Acquiring a near-term launch opportunity of a largely de-risked asset with limited competition which enhances sustainable growth of the company with significant upside potential from additional indications  

Palovarotene inhibits excess bone morphogenetic protein (BMP) signaling which is linked to the progression of FOP and MO, two well-characterized, ultra-rare/rare and severely-disabling bone disorders for which there are no treatment options available.  

meek meek

David Meek, Chief Executive Officer of Ipsen

“The acquisition of Clementia Pharmaceuticals accelerates the ongoing transformation of Ipsen as we are successfully executing on our external innovation strategy to identify and acquire innovative medicines to serve patients with unmet medical needs. Through this transaction, we will gain scientific expertise, exceptional talent and a cornerstone ultra-rare disease drug candidate with rare pediatric disease and breakthrough therapy designations, potential U.S. approval in 2020 and additional indications to follow. We look forward to working closely with Clementia to successfully integrate two companies that share a similar patient-centric culture and the ambition to deliver new treatments to patients with unmet medical needs.”

Clarissa

Dr. Clarissa Desjardins, Chief Executive Officer of Clementia

“I am proud of the entire Clementia team, whose tireless efforts have rapidly advanced palovarotene towards a planned NDA submission, and we are all grateful for the dedication of the patient community and our clinical trial investigators who have supported us along the way. Ipsen’s global commercial presence and capabilities will expedite our shared vision of bringing palovarotene to patients around the world as quickly as possible. We anticipate a smooth transition of our operations into the Ipsen organization that will continue Clementia’s vision of delivering palovarotene to patients worldwide.” 

About Fibrodysplasia Ossificans Progressiva (FOP)  

FOP is an ultra-rare, severely disabling disorder characterized by heterotopic ossification (HO), or bone that forms outside the normal skeleton, in muscles, tendons or soft tissue. In FOP, HO progressively restricts movement by locking joints, leading to a cumulative loss of function, progressive disability, and increased risk of early death. FOP is caused by a mutation in the ACVR1 gene, resulting in excess signaling in the bone morphogenetic pathway, a key pathway controlling bone growth and development, by way of both ligand-dependent and independent mechanisms. The prevalence of FOP is approximately 1.3 individuals per million lives, or approximately 9,000 globally. There are currently no approved treatments for FOP.

About Multiple Osteochondromas (MO)  

MO, also called multiple hereditary exostoses (MHE), is a rare, severely disabling, progressive, chronic disease in which multiple benign bone tumors, also known as osteochondromas (OCs) or osteocartilaginous exostoses, develop on bones. MO is typically diagnosed in early childhood when OCs become visible with a median age at diagnosis of four years. Because of their development around joints, children develop limb deformity and restricted movement as they grow. Today, the only available treatments for MO are surgery and palliative care, and many patients will undergo surgery, some as many as 30 surgeries, before adulthood. MO is estimated to affect 20 individuals per million lives, or approximately 150,000 globally. MO is among the most common inherited bone disorders with multiple family members in multiple generations affected.

Conference call

Ipsen will host a conference call and web conference (available at www.ipsen.com) today to discuss this announcement. Participants should dial in approximately 5 to 10 minutes prior to the start. No reservation is required to participate in the conference call.


A replay will be available for seven days on Ipsen’s website: www.ipsen.com  


Contacts


IPSEN

Media  

Christian Marcoux – Europe Senior Vice President, Corporate Communications + 33 (0) 6 71 58 11 46 Christian.marcoux@ipsen.com

Karla MacDonald – North America Vice President, NA Communications and Patient Advocacy + 1 (857) 332-3467 Karla.macdonald@ipsen.com

Ian Weatherhead – United Kingdom Vice President, Corporate External Communications + 44 (0) 7584 230549 Ian.weatherhead@ipsen.com

Financial Community  

Eugenia Litz Vice President, Investor Relations +44 (0) 1753 627721 eugenia.litz@ipsen.com

Myriam Koutchinsky Investor Relations Manager +33 (0)1 58 33 51 04 myriam.koutchinsky@ipsen.com


CLEMENTIA

Media and Financial Community  

Joseph Walewicz – Clementia Pharmaceuticals 

EVP, Business and Corporate Development

+ 1 (514) 940-1080 investors@clementiapharma.com